Monica Brackney
Yale University
15 Papers
5 Citations
Monica Brackney is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Cervical intraepithelial neoplasia. The author has an hindex of 5, co-authored 9 publications.
Chat about Author
Papers
Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008–2015
Julia W. Gargano,Ina U. Park,Marie R. Griffin,Linda M. Niccolai,Melissa Powell,Nancy M. Bennett,Michelle L Johnson Jones,Erin Whitney,Manideepthi Pemmaraju,Monica Brackney,Nasreen Abdullah,Mary Scahill,Rebecca M. Dahl,Angela A. Cleveland,Elizabeth R. Unger,Lauri E. Markowitz +15 more
TL;DR: From 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 years, consistent with a population-level impact of HPV vaccination.
53
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
Tamara Pilishvili,Ryan Gierke,Katherine E. Fleming-Dutra,Jennifer L. Farrar,Nicholas M. Mohr,David A. Talan,Anusha Krishnadasan,Karisa K. Harland,Howard A. Smithline,Peter C. Hou,Lilly C. Lee,Stephen C. Lim,Gregory J. Moran,Elizabeth Krebs,Mark T Steele,David G. Beiser,Brett A. Faine,John P. Haran,Utsav Nandi,Walter A. Schrading,Brian Chinnock,Daniel J. Henning,Frank LoVecchio,Jane Lee,Devra Barter,Monica Brackney,Scott K. Fridkin,Kaytlynn Marceaux-Galli,Sarah Lim,Erin C Phipps,Ghinwa Dumyati,Rebecca Pierce,Tiffanie M. Markus,Deverick J. Anderson,Amanda K. Debes,Michael Y. Lin,Jeanmarie Mayer,Jennie H. Kwon,Nasia Safdar,Marc Fischer,Rosalyn J. Singleton,Nora Chea,Shelley S. Magill,Jennifer R. Verani,Stephanie J. Schrag +44 more
TL;DR: The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the vir...
17
HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016
Julia Warner Gargano,Nancy McClung,Rayleen M. Lewis,Ina U. Park,Erin Whitney,Jessica L Castilho,Manideepthi Pemmaraju,Linda M. Niccolai,Monica Brackney,Emilio DeBess,Sara Ehlers,Nancy M. Bennett,Mary Scahill,Angela A. Cleveland,Troy D. Querec,Elizabeth R. Unger,Lauri E. Markowitz +16 more
TL;DR: Declines in cervical intraepithelial neoplasia grades 2-3 and adenocarcinoma in situ (CIN2+) observed among young women suggest impact from human papillomavirus (HPV) vaccination and a declining trend in HPV31-Cin2+ is consistent with cross-protection from vaccination.
16
Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
Ian D. Plumb,Melissa Briggs Hagen,Ryan Wiegand,Ghinwa Dumyati,Christopher J Myers,Karisa K. Harland,Anusha Krishnadasan,Jade James Gist,Glen Abedi,Katherine E. Fleming-Dutra,Nora Chea,Jane E. Lee,Melissa Kellogg,Alexandra Edmundson,Amber Britton,Lucy E. Wilson,S. Lovett,Valerie Ocampo,Tiffanie M. Markus,Howard A. Smithline,Peter C Hou,Lilly Lee,William Mower,Fernand Rwamwejo,Mark T Steele,Stephen C. Lim,Walter A. Schrading,Brian Chinnock,David G. Beiser,Brett Faine,John P. Haran,Utsav Nandi,Anne K. Chipman,Frank LoVecchio,Stephanie A. Eucker,Jon Femling,Matthew Fuller,Richard E. Rothman,Marcel E. Curlin,David A. Talan,Nicholas M. Mohr,Christopher Watts,Matthew McCullough,Sankan Nyanseor,Erin Licherdell,Alexander Peebles,Joelle Nadle,Helen Johnston,Monica Brackney,Scott Fridkin,Kaytlynn Marceaux-Galli,Ruth Lynfield,Rebecca Pierce,H. Keipp Talbot,Jillian Tozloski,Dean M. Hashimoto,Monica Bahamon,E. Krebs,Amy M. Stubbs,Michelle Huber,James C. Crosby,Sara Roy,Gregory Volturo,James Galbraith,Megan R. Fuentes,Jennifer Smith,Leslie Olivia Hopkins,Joseph Stuppy,Gaby Dashler,M. Wahedi +69 more
TL;DR: Moderate initial protection against symptomatic SARS-CoV-2 infection by remaining up-to-date with COVID-19 vaccines is indicated, and protection waned after two months.
9
Human Papillomavirus 16/18–Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty
Monica Brackney,Julia W. Gargano,Susan E. Hannagan,James Meek,Troy D. Querec,Linda M. Niccolai +5 more
TL;DR: Differences were observed in declines in the proportion of human papillomavirus 16/18 lesions by area-based measures since the introduction ofhuman papillmavirus vaccines, with greater and earlier declines in areas with fewer residents living in poverty and racial minorities.
6